SKYE vs. CTNM
SKYE (Skye Bioscience, Inc) and CTNM (Contineum Therapeutics, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, SKYE returned -65.41% vs 179.82% for CTNM. At a 0.21 correlation, their price movements are largely independent.
Performance
SKYE vs. CTNM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SKYE achieves a 3.35% return, which is significantly lower than CTNM's 7.96% return.
SKYE
- 1D
- 0.61%
- 1M
- -11.67%
- YTD
- 3.35%
- 6M
- -35.97%
- 1Y
- -65.41%
- 3Y*
- -42.50%
- 5Y*
- -55.62%
- 10Y*
- -39.35%
CTNM
- 1D
- -1.12%
- 1M
- -14.25%
- YTD
- 7.96%
- 6M
- 12.39%
- 1Y
- 179.82%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
SKYE vs. CTNM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
SKYE Skye Bioscience, Inc | 3.35% | -73.51% | -74.46% |
CTNM Contineum Therapeutics, Inc | 7.96% | -21.98% | -4.87% |
Correlation
The correlation between SKYE and CTNM is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Apr 8, 2024 | 0.21 |
Fundamentals
SKYE:
$30.75M
CTNM:
$460.76M
SKYE:
-$1.45
CTNM:
-$1.91
SKYE:
3.41
CTNM:
1.84
SKYE:
$0.00
CTNM:
$0.00
SKYE:
-$180.01K
CTNM:
-$245.00K
SKYE:
$10.92M
CTNM:
-$62.61M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SKYE vs. CTNM — Risk / Return Rank
SKYE
CTNM
SKYE vs. CTNM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Skye Bioscience, Inc (SKYE) and Contineum Therapeutics, Inc (CTNM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SKYE | CTNM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.63 | ||
| Sortino ratioReturn per unit of downside risk | -3.19 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.34 | -0.39 |
| Calmar ratioReturn relative to maximum drawdown | -0.75 | 6.06 | -6.81 |
| Martin ratioReturn relative to average drawdown | -1.00 | 13.94 | -14.94 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SKYE | CTNM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.57 | 2.06 | -2.63 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.43 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.29 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.36 | -0.12 | -0.24 |
Drawdowns
SKYE vs. CTNM - Drawdown Comparison
The maximum SKYE drawdown since its inception was -99.96%, which is greater than CTNM's maximum drawdown of -84.37%. Use the drawdown chart below to compare losses from any high point for SKYE and CTNM.
Loading charts...
Drawdown Indicators
| SKYE | CTNM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.96% | -84.37% | -15.59% |
Max Drawdown (1Y)Largest decline over 1 year | -87.85% | -29.84% | -58.01% |
Max Drawdown (3Y)Largest decline over 3 years | -96.79% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -98.79% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -99.83% | — | — |
Current DrawdownCurrent decline from peak | -99.94% | -43.26% | -56.68% |
Average DrawdownAverage peak-to-trough decline | -94.95% | -41.12% | -53.83% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 65.33% | 12.96% | +52.37% |
Volatility
SKYE vs. CTNM - Volatility Comparison
Skye Bioscience, Inc (SKYE) has a higher volatility of 28.43% compared to Contineum Therapeutics, Inc (CTNM) at 16.21%. This indicates that SKYE's price experiences larger fluctuations and is considered to be riskier than CTNM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SKYE | CTNM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 28.43% | 16.21% | +12.22% |
Volatility (6M)Calculated over the trailing 6-month period | 63.71% | 48.25% | +15.46% |
Volatility (1Y)Calculated over the trailing 1-year period | 115.70% | 88.08% | +27.62% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 130.81% | 83.28% | +47.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 137.36% | 83.28% | +54.08% |
Dividends
SKYE vs. CTNM - Dividend Comparison
Neither SKYE nor CTNM has paid dividends to shareholders.
Financials
SKYE vs. CTNM - Financials Comparison
This section allows you to compare key financial metrics between Skye Bioscience, Inc and Contineum Therapeutics, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SKYE and CTNM have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SKYE has higher volatility (28.43%) compared to CTNM (16.21%). In terms of maximum drawdown, SKYE dropped -99.96% vs CTNM's -84.37%.
CTNM currently has the higher Sharpe Ratio (2.06 vs -0.57), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SKYE and CTNM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer